Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma

Journal Article · Thu Sep 01 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2005.01.058· OSTI ID:20698531

Muller, Karin ^[1]; Nowak, Peter ^[1]; Pan, Connie de ^[1]; Marijnissen, Johannes P ^[1]; Paridaens, Dion A ^[2]; Levendag, Peter ^[1]; Luyten, Gre P.M. ^[3]

---

1. Department of Radiation Oncology, Erasmus Medical Center, Rotterdam (Netherlands)
2. Eye Hospital Rotterdam, Rotterdam (Netherlands)
3. Department of Ophthalmology, Erasmus Medical Center, Rotterdam (Netherlands)

Purpose: To study the effectiveness and acute side effects of fractionated stereotactic radiation therapy (fSRT) for uveal melanoma. Methods and Materials: Between 1999 and 2003, 38 patients (21 male, 17 female) were included in a prospective, nonrandomized clinical trial (mean follow-up of 25 months). A total dose of 50 Gy was given in 5 consecutive days. A blinking light and a camera (to monitor the position of the diseased eye) were fixed to a noninvasive relocatable stereotactic frame. Primary end points were local control, best corrected visual acuity, and toxicity at 3, 6, 12, and 24 months, respectively. Results: After 3 months (38 patients), the local control was 100%; after 12 months (32 patients) and 24 months (15 patients), no recurrences were seen. The best corrected visual acuity declined from a mean of 0.21 at diagnosis to 0.06 2 years after therapy. The acute side effects after 3 months were as follows: conjunctival symptoms (10), loss of lashes or hair (6), visual symptoms (5), fatigue (5), dry eye (1), cataract (1), and pain (4). One eye was enucleated at 2 months after fSRT. Conclusions: Preliminary results demonstrate that fSRT is an effective and safe treatment modality for uveal melanoma with an excellent local control and mild acute side effects. The follow-up should be prolonged to study both long-term local control and late toxicity.

• OSTI ID: 20698531
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 63, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2005.01.058; PII: S0360-3016(05)00139-2; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CATARACTS
CLINICAL TRIALS
DIAGNOSIS
FATIGUE
HAIR
MELANOMAS
PAIN
PATIENTS
RADIATION DOSES
RADIOTHERAPY
SIDE EFFECTS
TOXICITY